Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and treatment of acute episodes of iTTP that included daratumumab

	Patient 1	Patient 2
Characteristics
Sex	Male	Female
Age at presentation, y	32	31
Ethnicity	White	White
BMI, kg/m²	32	32
Type of iTTP episode	Relapse	First
N of previous iTTP episodes	3	0
Associated disease	None	Hypothyroidism
Laboratory values at presentation (current iTTP episode)
ADAMTS13 activity (normal range, >51%), %	<5	<5
ADAMTS13 inhibitor, BU/mL	>2	>2
Hemoglobin concentration (normal range, 134-170 [men] and 117-153 [women]), g/L	140	108
Platelet count (normal range, 143-400), × 10⁹/L	6	5
Lactate dehydrogenase (normal range, 240-480), U/L	2000	978
Total bilirubin (normal range, <21), μmol/L	54	39.7
Creatinine (normal range, 62-106), μmol/L	105	54
High-sensitivity troponin	Not elevated	Elevated
Treatment
PE sessions	7	15
Corticosteroids	Yes	Yes
Caplacizumab, d	32	121
Rituximab, n of doses	4	4
Daratumumab, n of doses	4	6
Follow-up, wk after last dose of daratumumab	14	10

	Patient 1	Patient 2
Characteristics
Sex	Male	Female
Age at presentation, y	32	31
Ethnicity	White	White
BMI, kg/m²	32	32
Type of iTTP episode	Relapse	First
N of previous iTTP episodes	3	0
Associated disease	None	Hypothyroidism
Laboratory values at presentation (current iTTP episode)
ADAMTS13 activity (normal range, >51%), %	<5	<5
ADAMTS13 inhibitor, BU/mL	>2	>2
Hemoglobin concentration (normal range, 134-170 [men] and 117-153 [women]), g/L	140	108
Platelet count (normal range, 143-400), × 10⁹/L	6	5
Lactate dehydrogenase (normal range, 240-480), U/L	2000	978
Total bilirubin (normal range, <21), μmol/L	54	39.7
Creatinine (normal range, 62-106), μmol/L	105	54
High-sensitivity troponin	Not elevated	Elevated
Treatment
PE sessions	7	15
Corticosteroids	Yes	Yes
Caplacizumab, d	32	121
Rituximab, n of doses	4	4
Daratumumab, n of doses	4	6
Follow-up, wk after last dose of daratumumab	14	10

BMI, body mass index; BU, Bethesda units.